Checkpoint Therapeutics Announces Publication Of Cosibelimab Pivotal Trial Results In The Journal For ImmunoTherapy Of Cancer
Portfolio Pulse from Benzinga Newsdesk
Checkpoint Therapeutics has announced the publication of results from a pivotal trial of cosibelimab, a potential best-in-class anti-PD-L1 antibody, in patients with metastatic cutaneous squamous cell carcinoma. The study found cosibelimab to have a robust and clinically meaningful objective response rate, with durable responses and a well-tolerated safety profile. The company is working with the FDA towards a January 3, 2024, action date for their Biologics License Application for cosibelimab.
October 18, 2023 | 12:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Checkpoint Therapeutics' cosibelimab shows promising results in a pivotal trial, potentially positioning the company for a successful Biologics License Application review by the FDA.
The positive results from the pivotal trial of cosibelimab could significantly boost Checkpoint Therapeutics' prospects. The company's ongoing work with the FDA towards a Biologics License Application review for cosibelimab indicates a potential new revenue stream if the application is successful.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100